Known activities of CD4⁺ T cells in antiviral immunity

CD4⁺ T cells contribute a myriad of activities in protective immunity against viruses that are initiated by infection or by vaccination. These activities can be broadly separated into distinct categories that include recruitment of key lymphoid cell populations into secondary lymphoid tissue or sites of pathogen infection, provision of help for expansion or function of other effector cells, or offering direct effector function through production of cytokines or cell-mediated cytotoxicity. One key activity of CD4⁺ T cells is recruitment of other lymphoid cells: CD4⁺ T cells can promote engagement of CD8⁺ T cells with dendritic cells (DCs) in secondary lymphoid tissue (Beuneu et al., 2006; Castellino et al., 2006), cause influx of lymphoid cells into draining lymph node (Kumamoto et al., 2011), and recruit innate or antigen-specific effectors to the site of viral replication (Nakanishi et al., 2009; Strutt et al., 2010; Teijaro et al., 2010). Whether these CD4⁺ T cells are ever limiting in response to infection, and can thus serve as predictors of disease susceptibility, is not yet known.

The role of CD4⁺ T cell help in CD8⁺ T cell priming, effector function, and memory has been extensively studied in recent years (Wiesel and Oxenius, 2012). Although such help may not be as critical for viruses that offer many CD8 epitopes (Sette and Rappuoli, 2010) and/or generate potent activating signals from DCs through strong Toll-like receptor engagement, it may be critical for pathogens that antagonize the immune response by down-regulating the activity of proinflammatory mediators. It is also likely to be essential for the development of memory CD8⁺ T cells that can be recalled upon challenge (Williams et al., 2006). With chronic viral infections, the role and importance of CD4⁺ T cell help is even more profound. Under these conditions, CD8⁺ T cells rely on continued rounds of expansion for which CD4⁺ T cell cytokine production is critical (Elsaesser et al., 2009; Fröhlich et al., 2009; Yi et al., 2009; Aubert et al., 2011).

That CD4⁺ T cell help is needed for high-affinity, neutralizing antibody responses by B cells has been known for decades, but more recent work has identified the follicular helper CD4⁺ T cells (Tfh) as the key subset that mediates this function (Crotty, 2011; King, 2011). Recent identification of cells with Tfh lineage markers and functional activity in circulation of human subjects (Chevalier et al., 2011; Morita et al., 2011) raises the possibility that quantifying this subset may be useful as a biomarker for future vaccine responses, particularly if coupled with analyses of CD4 specificity. Finally, increasing evidence supports the view that CD4⁺ T cells have direct roles as effectors in antiviral immunity either through provision of key antiviral cytokines or through direct cytotoxicity (Swain et al., 2012). Defining the complexity of CD4⁺ T cells has provided a pallet to dissect protective immunity in different human populations for distinct viral pathogens, but improved and more sophisticated assays are needed to reveal if the activities of CD4 T cells ever truly limit protective responses.

Complexity in assessing contribution of CD4⁺ T cells

There are several major difficulties in assessing the contributions of CD4⁺ T cells to the control of virus infections. There is the breadth of the CD4⁺ T cell repertoire, which for influenza virus can include up to 100 distinct peptides specificities (Chaves et al., 2012). A recent study of human responses to vaccinia virus using a whole-proteome approach demonstrated that a mean of 39 open reading frames, each of which likely contain multiple peptide epitopes, were recognized by vaccinees (Jing et al., 2008). Limited epitope sampling through use of a few favored peptides or limited antigens may prevent successful identification of the true correlates of protection as only some subsets of CD4⁺ T cells may participate in particular responses. For example, in HIV, subsets of lymphoid cells distinguish those that control infection versus those that do not (Porichis and Kaufmann, 2011; Thèze et al., 2011). Recent comprehensive screening of a large cohort of infected subjects using peptides representing the entire proteome has revealed that differences in the CD4⁺ T cell immunodominance profile distinguished those who control the virus compared with those that progress (Ranasinghe et al., 2012). The overall breadth of the response was inversely correlated with viral load, and the ratios of Gag-specific to Env-specific CD4⁺ T cells determined virus progression.

CD4⁺ T cell help for antibody responses is another situation that links CD4⁺ T cell specificity and functionality, because delivery of help for antibody responses normally requires that the B cell and CD4⁺ T cell recognize epitopes from the same antigen. Such help for antibody responses is restricted primarily to follicular helper cells (Crotty, 2011; King, 2011). Tracking cells with irrelevant specificities or the wrong function may only add noise to assessments of CD4⁺ T cell functionality. Additionally, in humans, some CD4⁺ T cells may be invisible to experimentation because of restricted recirculation, and thus low abundance in peripheral blood. Finally, rapid and transient kinetics of the responses detected in peripheral blood after pathogen infection or vaccination (Weinfurter et al., 2011; Li et al., 2012; Riou et al., 2012) may diminish detection and characterization of the responding CD4⁺ T cells in humans if sampled at the wrong time. Incomplete or inadequate consideration of these factors can lead to false-negative assessments of the role of CD4⁺ T cell responses to infection and vaccination, particularly in human subjects, in whom there are significant barriers to tissue sampling and response assessment.

In this issue, Zhou et al. (2012) track CD4⁺ and CD8⁺ T cell responses over time during acute resolving hepatitis A virus (HAV) infection in chimpanzees. The studies were revealing because of the detailed and comprehensive nature of the study design. Frequent sampling of peripheral blood allowed simultaneous tracking of responses and viral gene expression, both during the acute phase (weeks 1–6) and long term. Sampling of serum, fecal material, and liver for HAV RNA allowed assessment of virus expansion, control, and rebound. The authors also sampled liver tissue biweekly for HAV-specific CD4⁺ and CD8⁺ T cells. CD4⁺ T cell specificity and functionality was probed using pools of HAV peptides representing the entire HAV genome in conjunction with intracytoplasmic staining for the key cytokines IL-2, TNF, IL-21, and IFN-γ. Surprisingly, these studies revealed few kinetic correlates between CD8⁺ T cell activity and control of viremia. Rather, early expansion of multifunctional CD4⁺ T cells that produced IL-2 and IL-21 IFN-γ and TNF was observed, with contraction after clearance of the virus. The highly differentiated phenotype of CD4⁺ T cells early in the response, lacking in the CD8 compartment, was noteworthy because of the role IFN-γ and TNF in inhibiting HAV replication. These coordinate kinetics of expansion of virus and CD4⁺ T cells in this primate model of infection suggested that the virus-specific CD4⁺ T cells contributed to ultimate control of virus in vivo.

This work echoes the conclusion of Soghoian et al. (2012) in a recent broad survey of acutely HIV-infected subjects, in which HIV CD4⁺ and CD8⁺ T cells were tracked over time using peptide pools representing the major virus proteins, in parallel with virus progression. Strikingly, early expansion and phenotype of CD4⁺ T cells, but not CD8⁺ T cells, specific for HIV were most closely associated with virus control. Moreover, expansion of granule-positive, HIV-specific cytotoxic CD4⁺ T cells was most tightly correlated with a positive outcome. Similarly, a recently reported study by Wilkinson et al. (2012) explored the importance of CD4 T cells in protection from influenza in a challenge model in human subjects. As in the study by Zhou et al. (2012), and those of Soghoian et al. (2012), multiple parameters were tracked over time, including viral titers in nasal washes, symptom scores, serological conversion to neutralizing antibody, and T cell responses that were elicited by large pools of synthetic peptides representing the whole virus proteome. Strikingly, the strongest association was a correlation between increased levels of preexisting influenza-specific CD4⁺ T cells with increased virus clearance and reduced symptom score. Additionally, early CD4⁺ T cell responses to virus infection were characterized by production of IFN-γ and cytotoxic activity. These results collectively suggest that preexisting memory CD4⁺ T cells can be rapidly mobilized for protection against novel virus strains, and that these T cells exert direct antiviral activity. This result is in agreement with mouse models of sequential infection for protection against pandemic challenge (Alam and Sant, 2011) and surveys of human populations (Greenbaum et al., 2009; Ge et al., 2010). The protection observed in Wilkinson et al. (2012) can also be related to recent findings in animal models, showing that memory CD4⁺ T cells can promote rapid recruitment of innate effectors to the lung to establish an accelerated antiviral state (Strutt et al., 2010; Teijaro et al., 2010). Additionally, recent studies in both murine influenza (Brown et al., 2012), human cytomegalovirus, and HIV (Soghoian and Streeck, 2010; Swain et al., 2012) suggest that CD4 T cell–mediated cytotoxicity of infected cells can play a critical function in viral clearance (Appay, 2004; Casazza et al., 2006; Soghoian et al., 2012). Thus, although the balance between CD4⁺ and CD8⁺ T cell–mediated effects are different for individual viruses, accumulating evidence points to the direct role of CD4⁺ T cells in protective immunity to many viruses.

The comprehensive analysis of CD4⁺ T cell responses by Zhou et al. (2012), as well as the other recent studies highlighted in this minireview, provides provocative evidence of the essential role of CD4⁺ T cells in protection from virus infection in humans and primates. Coupled with mechanistic studies in animal models, advances in discovery (Koelle, 2003; Sette and Rappuoli, 2010; Chaves et al., 2012) and organization (Vita et al., 2010) of T cell epitopes, increasingly sophisticated T cell phenotyping (Nepom, 2012; Newell et al., 2012), and gene expression profiling (Chaussabel et al., 2010; Nakaya et al., 2011) all provide roadmaps to select optimal vaccination strategies that elicit the preferred CD4⁺ T cells for the most effective protective immunity to virus infection.